High-avidity T cells are preferentially tolerized in the tumor microenvironment

Cancer Research

Volumn 73, Issue 2, 2013, Pages 595-604

  Zhu, Ziqiang ^a   Singh, Vinod ^a,d   Watkins, Stephanie K ^a   Bronte, Vincenzo ^b   Shoe, Jennifer L ^c   Feigenbaum, Lionel ^c   Hurwitz, Arthur A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF VERONA   (Italy)

^d SHOOLINI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DOPACHROME TAUTOMERASE; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DEPIGMENTATION; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; FEMALE; IMMUNE TOLERANCE; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84872562269     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1123     Document Type: Article

References (46)

1. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002;188: 136-46.
2. Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Germeraad WT. Expression of tumor-associated differentiation antigens,MUC1glycoforms and CEA, in human thymic epithelial cells: implications for selftolerance and tumor therapy. Cancer Res 2007;67: 3919-26.
3. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, et al. Identification of newHER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999;163: 1037-44.
4. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000;13: 829-40.
5. Kawai K, Ohashi PS. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 1995;374: 68-9.
6. Hernandez J, Aung S, Redmond WL, Sherman LA. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med 2001;194: 707-17.
7. Herndon JM, Stuart PM, Ferguson TA. Peripheral deletion of antigenspecific T cells leads to long-term tolerance mediated by CD8+ cytotoxic cells. J Immunol 2005;174: 4098-104.
8. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005;22: 275-84.
9. Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a selfantigen into an antitumor response. J Immunol 2005;175: 1456-63.
10. Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000;60: 6995-7001.
11. Bullock TN, Mullins DW, Colella TA, Engelhard VH. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol 2001;167: 5824-31.
12. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001;166: 1690-7.
13. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162: 989-94.
14. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC,HughesMS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114: 535-46.
15. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99: 16168-73.
16. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
17. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23: 2346-57.
18. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8: 299-308.
19. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, et al. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 2009;69: 6256-64.
20. Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 2009;183: 4848-52.
21. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 2007;178: 1268-76.
22. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008;68: 2993-3000.
23. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008;26: 677-704.
24. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207: 2187-94.
25. Singh V, Ji Q, Feigenbaum L, Leighty RM, Hurwitz AA. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J Immunother 2009;32: 129-39.
26. De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, et al. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanomaspecific CD8+ T lymphocytes. Cancer Res 2004;64: 8068-76.
27. Currier JR, Robinson MA. Spectratype/immunoscope analysis of the expressed TCR repertoire. Curr Protoc Immunol 2001;Chapter 10:Unit 10 28.
28. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 1999;10: 485-92.
29. Wang XL, Altman JD. Caveats in the design of MHC class I tetramer/ antigen-specific T lymphocytes dissociation assays. J Immunol Methods 2003;280: 25-35.
30. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFNproducing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006;177: 3260-5.
31. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011;121: 1361-72.
32. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011;71: 5393-9.
33. Heath WR, Karamalis F, Donoghue J, Miller JF. Autoimmunity caused by ignorant CD8+ T cells is transient and depends on avidity. J Immunol 1995;155: 2339-49.
34. Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci USA 2008;105: 12643-4.
35. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6: 836-48.
36. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor-cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class-I major histocompatibility complex expression. Cancer Res 1991;51: 1185-9.
37. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5: 263-74.
38. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222: 162-79.
39. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6: 295-307.
40. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 2009;86: 1105-9.
41. Wasiuk A, de Vries VC, Hartmann K, Roers A, Noelle RJ. Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol 2009;155: 140-6.
42. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314: 126-9.
43. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8 +and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 2005;65: 1570-6.
44. Zhao Y, Bennett AD, Zheng Z,WangQJ, Robbins PF, Yu LY, et al. Highaffinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007;179: 5845-54.
45. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med 2009;206: 463-75.
46. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27: 670-84.